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Toward personalized synchrotron microbeam radiation therapy 
Abstract 
Synchrotron facilities produce ultra-high dose rate X-rays that can be used for selective cancer treatment 
when combined with micron-sized beams. Synchrotron microbeam radiation therapy (MRT) has been 
shown to inhibit cancer growth in small animals, whilst preserving healthy tissue function. However, the 
underlying mechanisms that produce successful MRT outcomes are not well understood, either in vitro or 
in vivo. This study provides new insights into the relationships between dosimetry, radiation transport 
simulations, in vitro cell response, and pre-clinical brain cancer survival using intracerebral gliosarcoma 
(9LGS) bearing rats. As part of this ground-breaking research, a new image-guided MRT technique was 
implemented for accurate tumor targeting combined with a pioneering assessment of tumor dose-
coverage; an essential parameter for clinical radiotherapy. Based on the results of our study, we can now 
(for the first time) present clear and reproducible relationships between the in vitro cell response, tumor 
dose-volume coverage and survival post MRT irradiation of an aggressive and radioresistant brain cancer 
in a rodent model. Our innovative and interdisciplinary approach is illustrated by the results of the first 
long-term MRT pre-clinical trial in Australia. Implementing personalized synchrotron MRT for brain cancer 
treatment will advance this international research effort towards clinical trials. 
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toward personalized synchrotron 
microbeam radiation therapy
elette engels  1,2, Nan Li1,2, Jeremy Davis1, Jason paino1, Matthew cameron1, 
Andrew Dipuglia1, Sarah Vogel  1, Michael Valceski1, Abass Khochaiche1, Alice o’Keefe1, 
Micah Barnes  3, Ashley cullen1,4, Andrew Stevenson3, Susanna Guatelli1,2, 
Anatoly Rosenfeld1,2, Michael Lerch1,2, Stéphanie corde  1,2,5 & Moeava tehei  1,2 ✉
Synchrotron facilities produce ultra-high dose rate X-rays that can be used for selective cancer 
treatment when combined with micron-sized beams. Synchrotron microbeam radiation therapy 
(MRT) has been shown to inhibit cancer growth in small animals, whilst preserving healthy tissue 
function. However, the underlying mechanisms that produce successful MRT outcomes are not well 
understood, either in vitro or in vivo. this study provides new insights into the relationships between 
dosimetry, radiation transport simulations, in vitro cell response, and pre-clinical brain cancer survival 
using intracerebral gliosarcoma (9LGS) bearing rats. As part of this ground-breaking research, a 
new image-guided MRT technique was implemented for accurate tumor targeting combined with a 
pioneering assessment of tumor dose-coverage; an essential parameter for clinical radiotherapy. Based 
on the results of our study, we can now (for the first time) present clear and reproducible relationships 
between the in vitro cell response, tumor dose-volume coverage and survival post MRT irradiation of 
an aggressive and radioresistant brain cancer in a rodent model. our innovative and interdisciplinary 
approach is illustrated by the results of the first long-term MRT pre-clinical trial in Australia. 
Implementing personalized synchrotron MRT for brain cancer treatment will advance this international 
research effort towards clinical trials.
In the last 30 years, treatment outcomes for brain cancer in children and young adults have remained at a 
stand-still. Despite significant progress in brain cancer treatment involving surgical resection, radiotherapy and 
chemotherapeutics, the inherent resistance of these cancers challenge treatment success1. The prognosis is even 
poorer for high-grade gliosarcomas and glioblastoma multiformes (GBMs), and treatments must balance the 
risk of neurological deficits2. Consequently, there has been little improvement in brain and CNS cancer survival 
between 1990 and 2016 (only −2.2% difference in mortality) despite a 17% increase in incidence3. Due to the 
extremely invasive nature of high-grade brain cancers, treatments remain challenging and research into novel 
therapies with improved outcomes are still needed.
Synchrotron microbeam radiation therapy (MRT) is an innovative cancer treatment technique proposed 
in 19924. MRT implements spatially fractionated beams of kilovoltage radiation that are tens of microns in 
width and spaced hundreds of micrometers apart. The synchrotron radiation source is extremely brilliant and 
non-divergent, capable of producing a high-flux of photons leading to irradiation dose-rates upwards of thou-
sands of Gray (Gy) per second5. The synchrotron microbeam array contains micron-sized beamlets that promote 
radiosurgical treatment of cancers (with in-beam, or peak doses, of hundreds of Gray). Further, normal tissue 
sparing is observed, due to the biologically tolerable dose between microbeams (defined as the valley dose). 
Numerous pre-clinical studies support the reduction in normal tissue damage with MRT, while effectively treat-
ing the cancer5–8.
Amongst the synchrotron facilities that provide the technical pre-requisites to explore MRT, there is signif-
icant variation between treatment techniques including beam dimensions and spacing, beam filtration, image 
guidance, dose rates and doses. A major uncertainty in prescribing MRT is relating these parameters to systematic 
tumor control. Early studies4,9–12 use skin entrance doses as a standard, providing insufficient knowledge of the 
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tumor dose coverage at depth. A few recent studies6,12–15 describe the valley and peak dose in the brain at depth, 
however, there is scarce individualized tumor volume coverage, as typically used in clinics. Image guidance in 
MRT is necessary to ensure tumor coverage but is not implemented in all studies. Le Duc et al.16 is among the few 
studies to consider co-registration of images and positioning animals accordingly to better target brain tumors. 
Spatially fractionated MRT doses are challenging to compare with existing modalities. Studies such as Smyth et 
al.17 have surmised that the MRT valley dose is the most relatable parameter to standard broad beam treatments, 
yet the effect of the dose spatial modulation is not well understood.
Furthermore, direct relationships between in vitro and in vivo MRT studies are scarce. While in vitro studies 
are performed to discern the response of cells to MRT18,19, they are not correlated directly to in vivo studies. 
Ideally, as the current focus of clinical practice is personalization, patterns in in vitro studies should be used to 
predict in vivo responses in an effort to personalize MRT for better patient specificity. MRT could also benefit 
from more clinically oriented approaches to treatment planning. The MRT dose coverage of the tumor volume 
and organs at risk (OAR) must be further investigated. This requires knowledge of the peak and valley dose dis-
tribution in the anatomy, and MRT related normal tissue toxicities.
Normal tissue responses to MRT show good tolerance to valley doses greater than 18 Gy5–7,10,20–24. However, 
clinical signs in animals following MRT are not well documented. Brain tumor treatment in human patients can 
cause adverse effects, including tiredness, skin reactions, headaches, nausea, seizures and hair loss22. Previous 
pre-clinical MRT studies have few reports of early radiation symptoms, and there is no standard for symptom 
management for brain MRT to-date. No long-term side effects are typically found however, in terms of cell func-
tionality20, memory loss23, motor function and behavior24.
The future of MRT therefore requires the correlation of dosimetry and treatment planning, accurate imaging 
of brain tumors and image guidance, and reporting of clinical signs and symptom management. To date, there 
are no pre-clinical studies in MRT that combine the necessary dosimetry, image guidance, treatment planning 
and short- and long-term follow-up. This study is designed to demonstrate the necessary steps for optimiza-
tion of personalized pre-clinical MRT of high grade brain cancer: treatment planning, radiobiological insights, 
image-guidance, and symptom management strategies.
Methods
Synchrotron radiation beam configuration and characterization. Irradiations were conducted 
using the dynamic mode option at hutch 2B of the Imaging and Medical Beamline (IMBL) at the Australian 
Synchrotron, 34.1 m from the source. The X-ray beam was produced via a 2–3.2 Tesla superconducting multipole 
wiggler. Full details of beam configurations available at IMBL for synchrotron broad beam (SBB) and microbeams 
are described by Stevenson et al.25. Microbeams were produced by passing the beam through a tungsten carbide 
multi-slit collimator (MSC); 8 mm thick, 40 mm wide and 4 mm high. This produced microbeams (50 µm in 
width and 400 µm pitch), as described in Stevenson et al.25. Due to the width of the intrinsic irradiation field size 
used (10 mm at the sample position), in vitro experiments required irradiation of 12.5 cm2 flasks in four columns. 
For in vivo experiments, a single column of unidirectional microbeams was used. The complete beam configura-
tion parameters for cell and animal experiments are shown in Table 1, also found in Dipuglia et al.26.
In vitro experiments, dosimetry and treatment verification. The dosimetric protocol for SBB and 
MRT at the IMBL is outlined in previous publications25–31. Briefly, it involves characterizing the pre-filtered SBB 
uniform in custom designed RMI-457 Gammex Solid Water® phantoms (Gammex-RMI, Middleton, WI, USA) 
using a PinPoint ionization chamber (IC) (PTW 31014, Freiburg, Germany), calibrated to a traceable standard. 
A micron-scale spatial resolution X-Tream dosimeter27,28 was then calibrated at the same reference conditions: 
20 × 20 mm2 SBB field at a 20 mm depth. After the insertion of the MSC, the MRT field was characterized using 
the X-Tream system at 20 mm depth. Microbeam peak and valley doses, and the Peak-to-Valley Dose Ratio 
(PVDR) were measured for treatment planning. The valley was defined near-midway between microbeam peaks. 
Final validation was performed with complementary radiation transport simulations before cell and pre-clinical 
experiments.
Prior to every experiment, the final in vitro irradiation doses were verified at the same depth as the monolayer 
of cells (24 mm) within a 15 × 15 × 15 cm3 Gammex solid water® phantom30 with a 12.5 cm2 cell flask insert that 
Mode
Wiggler 
Field (T)
Filtration 
(mm)
Mean 
energy 
(keV)
Beam height (mm);
Beam width (cm);
Number of columns
Intrinsic dose rate 
(Gy/s) in Solid 
Water® PVDR
Result
Ref.
SBB
2 Cu (1.41)Al (2.82) 71.4 0.27;1; 4 40 at 24 mm N/A
Figs. 4, 5
Table 2
3 Cu (1.41),Cu (1.41) 95 0.49; 1; 4 205 at 24 mm N/A
Fig. 4
Table 2
MRT
2 Cu (1.41)Al (2.82) 71.4 0.27; 1; 4
40 (peak), 5 (valley)
at 24 mm 8.4 ± 1 Fig. 5
3 Cu (1.41)Al (2.82) 81 0.5; 0.8; 1
350 (peak), 5 (valley)
at 5.5 mm 71 ± 2 Figs. 6–8
Table 1. Beam configurations for SBB and MRT, in vitro and in vivo at the Australian Synchrotron IMBL. All 
intrinsic dose rates and beam geometry are measured at the sample position. PVDR uncertainty is evaluated 
within 1 standard deviation. Result references are shown to relate the parameters used to experimental data.
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is used to perform the irradiation. For MRT, the X-Tream dosimeter, a PTW microdiamond31, and Gafchromic® 
EBT3 film (24 hour post irradiation analysis only) were used to verify the dose. For SBB, Gafchromic® EBT3 film 
and PinPoint IC were used to confirm doses. For each irradiation, a film was placed on the back-side (down-
stream) of the cell flask to confirm the irradiation geometry (SBB or MRT).
In vivo experiments dosimetry and treatment verification. After calibration of the X-Tream dosim-
eter in the reference conditions, the dose was measured in a 25 × 25 × 50 mm3 Solid Water® phantom at 12.5 mm 
depth for the reference field. The MRT treatment field was further collimated with an 8 × 8 mm2 conformal mask 
and dosimetrically characterized by the X-Tream dosimeter at a 12.5 mm (reference) depth within the phantom. 
The peak dose, valley dose and PVDR were measured horizontally across 5 central microbeams and associated 
valley regions at a 5 and 10 μm sampling step size, respectively.
Experimental SBB IC measurements were compared with Geant4 radiation transport simulations modelling 
the experimental set-up for quality assurance purposes27. The Geant4 simulation (version 9.6, patch 4, and using 
the Livermore Polarized Physics List to model EM interactions) described by Dipuglia et al.26 was used to eval-
uate the MRT peak and valley doses at tumor depth. X-Tream measurements were made at a 12.5 mm reference 
depth in the Solid Water® phantom with precise quantification and tuning of the peak and valley dose using the 
vertical motor translation speed. Geant4 simulations were then validated with experimental dose measurements 
at 12.5 mm depth. The dose at tumor depth (5.5 mm) could then be calculated using the Monte Carlo simulation 
and the vertical translation speed adjusted to deliver the prescribed treatment dose. In this experiment, the pre-
scribed tumor valley dose was 15 Gy.
Figure 1A shows the microbeam lateral dose profile at the entrance and tumor depth, as simulated in Geant4. 
The peak and valley doses with respect to a range of depths in water are shown in Fig. 1B. This information was 
used to determine the MRT dose to the tumor and whole brain for a posteriori treatment planning purposes.
Treatment α (Gy−1) β (Gy−2) RER10
2T 0.124 ± 0.028 0.0162 ± 0.0042 1.27 ± 0.10
3T 0.740 ± 0.079 0.0371 ± 0.0212 4.07 ± 0.28
Conventional 
150 kVp X-rays 0.112 ± 0.030 0.0088 ± 0.0035 1
Table 2. Comparison of all broad beam treatments with regard to radiobiological parameters α and β 
(according to Eq. 1). The 2 T and 3 T treatment identifiers correspond to the different spectra and dose rate 
conditions indicated in Table 1. Dose Rate enhancement ratio (RER10) values measured at 10% survival are 
compared against the conventional 150 kVp X-ray treatment.
Figure 1. Geant4 Monte Carlo calculated 3 T (Cu/Al) microbeam dose profile (A) at the entrance (0.25 mm) 
and tumor depths (5.5 mm) in water. MRT irradiation depth dose curve (B) showing the peak (red) and 
valley (green) doses in water, overlaid with the micro-CT sagittal profile of a rat in this study to show the dose 
distribution in the rat and tumor (location indicated by white arrow). Monte Carlo calculated peak and valley 
doses were verified dosimetrically at 12.5 mm depth.
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In vitro protocols. Cell preparation. 9 L gliosarcoma (9LGS) is a native gliosarcoma of Fischer rats which 
contains glial components of glioblastoma multiforme and a sarcomatous component32. 9LGS cells were acquired 
from the European Collection of Cell Cultures (ECACC). The cells were cultured in T75 cm2 flasks containing 
complete Gibco® Dulbecco’s modified eagle medium (c-DMEM), i.e. with 10% foetal bovine serum (FBS) and 1% 
penicillin and streptomycin (PS). Cells were incubated at 37 oC and 5% (v/v) CO2. 9LGS cells were sub-cultured 
into T12.5 cm2 flasks (BD FalconTM) containing c-DMEM prior to irradiation.
Cell irradiation. 9LGS cells were irradiated at room temperature using clinical orthovoltage or synchrotron 
X-ray sources. Conventional broad beam (CBB) irradiation of 9LGS was performed at the Prince of Wales 
Hospital (Randwick, NSW, Australia) using orthovoltage X-rays. T12.5 cm2 flasks containing monolayer of 9LGS 
and 6 mm of c-DMEM were irradiated in horizontal position at a distance of 50 cm from the source in full scat-
ter conditions including Solid Water® below and adjacent to the cells. X-rays were generated using a Nucletron 
Oldelft Therapax DXT 300 Series 3 Orthovoltage x-ray machine (Nucletron B.V., Veenendaal, The Netherlands). 
The tube peak voltage was 150 kVp with a beam current of 20 mA, incident on a tungsten target and using down-
stream filtration of 3 mm Be and additional 0.35 mm of copper and 1.5 mm of aluminium (HVL = 0.68 mm Cu). 
These X-rays were used to irradiate the cells with a dose rate of 0.76 Gy/min for doses ranging from 1– 8 Gy at 
6 mm depth.
At the Australian Synchrotron, cells were irradiated upright in hutch 2B using the dynamic radiotherapy 
modality at the IMBL for MRT and SBB modes, as given in Table 1. T12.5 cm2 flasks containing a monolayer of 
9LGS were filled with Hank’s Balanced Salt Solution (HBSS), such that cells were located at 2.4 cm depth. Full 
scatter conditions were created by using a Gammex Solid Water® phantom material below and adjacent to the 
flask of cells. Irradiation of flasks was delivered at a minimum scanning rate of 10 mm/s which delivered 1 Gy or 
0.4 Gy in the valley to the cells for SBB and MRT, respectively. To cover the 12.5 cm2 area of the cells, the treatment 
was divided into several columns, shown in Table 1. Dose verification was performed as described above.
Figure 2. Location of the smallest 9LGS tumor using micro-CT imaging 11 days after injection shown in the 
red circle in transverse (left), coronal (middle) and sagittal (right) views. Burr hole location is shown (arrow).
Figure 3. CT anatomical images acquired day 11, and X-ray radiography alignment and MRT irradiation on 
day 12. Day 11 micro-CT coronal reconstruction showing target outline (A), 3D volume rendering of bony 
anatomy and alignment points (B), planar X-ray alignment (C), and MRT irradiation with film entry and exit 
verification (D). Red box shows the 8 × 8 mm2 MRT delivery field and tumor position (cross) inside (not to 
scale).
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Cell processing following irradiation. For clonogenic assays, cells were washed with DPBS and trypsinized before 
seeding 3 triplicates at low density into 100 mm petri dishes with 10 mL of c-DMEM. After 15 doubling times, 
each dish was washed with 5 mL DPBS (with Ca2+/Mg2+) and stained with a 1:3 (v/v) crystal violet solution 
with 2.3% crystal violet stock (Sigma Aldrich®) and 70% ethanol. The surviving colonies of 50 cells or more 
were counted and compared with the initial seeding number to determine the plating efficiency (PE). For each 
group, the surviving fraction (SF) was calculated by taking the ratio of the PE of the irradiated cells, by the PE 
of the non-irradiated control. Cell survival data was fitted using GraphPad Prism 7. MRT cell experiments were 
repeated twice, broad beam 1–4 times. Errors and error bars were evaluated using one standard deviation from 
the mean.
In vivo protocols. All operative procedures and animal care were in conformity with the guidelines of 
the Australian Code for the Care and Use of Animals for Scientific Purposes33 and under the approval of the 
University of Wollongong and Australian Synchrotron animal ethics committees agreements (AE17/05 and 
AS-2017-01).
tumor implantation and animal monitoring. A total of ten 7-week old inbred male F344/Arc (Fisher 
344) rats from the Animal Resource Centre, Canning Vale, Perth, Australia were housed at the Australian 
Figure 4. Comparison of synchrotron radiation (with wiggler fields of 2 T and 3 T in Table 1) and conventional 
orthovoltage radiation on 9LGS cell survival with respect to dose. Errors were determined from the standard 
deviation of several experiments.
Figure 5. 9LGS cell survival using a 2 T wiggler field SBB and MRT (valley dose shown), compared to CBB 
irradiation. Mean energy of X-rays is 66 keV. Errors were determined from the standard deviation of averages 
measured over 2 separate experiments. A polynomial fit was applied to the MRT survival curve for visual 
purpose.
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Synchrotron, Clayton, Victoria, Australia in individually ventilated cages containing Pura chips bedding, spe-
cialty irradiated feed, access to water and environmental enrichments in groups of 2 or 3. Rats were sub-grouped 
into MRT-treated or controls, with 5 animals per group.
All rats experienced 1 week of acclimation, before tumor implantation surgery at 8 weeks old. 2 hours prior 
to surgery, pre-emptive analgesia was provided by voluntary oral administration of 0.4 mg/kg buprenorphine in 
Nutella (Ferrero Australia Pty Ltd, Lithgow NSW, Australia). Prior to surgery, 9LGS cells were harvested from 
T75cm3 flasks by washing with DPBS, and trypsinizing for 5 minutes. Cells were washed and suspended twice in 
serum-free DMEM for injection.
Rats were inducted with 5% isoflurane in oxygen and general anesthesia (GA) was maintained with 2.5- 3% 
isoflurane. Ophthalmic lubricant was applied to protect the eyes and each rat was placed on a heat mat, monitored 
by PhysioSuite®, (Kent Scientific Corporation, Torrington CT USA). Vital signs including respiratory rate, body 
temperature and blood oxygen levels were monitored and maintained between 45–65 bpm, 37–38.5 oC, 95–100%, 
respectively. This ensured all rats recovered from surgery without complications.
Once stable under GA, the scalp was shaved, and the rat was placed on a small animal Kopf Model 900 ster-
eotaxic frame including microinjection unit (Kopf Instruments, Tujunga CA, USA). Bupivacaine was injected 
subcutaneously in the scalp for local analgesia. A solution of 10% povidone iodine antiseptic was then applied to 
the scalp and a disposable sterile plastic sheet covered the rat.
An aseptic environment was created to avoid complications post-surgery including sepsis34. Surgical drapes, 
instruments, and equipment and protective gear were autoclaved before surgery, with surgical equipment ster-
ilized for each rat35. A dorsal midline incision was made through the plastic sheet commencing posterior to the 
eyes and extending rostral to the ears. The skull was exposed, and any minor bleeds cauterized. A 0.6–0.8 mm 
burr hole was made at 3.5 mm to the right of the bregma crossing on the skull using a 1.4 mm K-wire.
The 9LGS cells at a concentration of 10,000 cells per µL were drawn into a 2 µL Neuros Hamilton syringe with 
a 30-gauge needle (Hamilton Company, Reno NV, USA) and was loaded on the microinjection unit. The syringe 
needle was inserted through the burr hole to a 6 mm depth into the caudate nucleus of the brain, over 2 minutes. 
Before injection, the syringe was retracted 0.5 mm to produce a void for the cells. 1 µL of cells was injected with 
the microinjection unit over 3 minutes. Before withdrawing the needle, cells were allowed to settle for 1 minute. 
The needle was extracted over 3 minutes. After needle withdrawal, the burr hole was disinfected with alcohol and 
the wound closed with polypropylene non-absorbable monofilament sutures.
Each rat was given fluid replacement subcutaneously prior to recovery and placed in a warmed recovery cage 
individually. After 15–20 minutes, fully conscious and mobile rats were returned to their home cage. 12 hours 
after surgery, another dose of buprenorphine was administered to maintain analgesia. Rats were monitored for 
post-surgical complications twice daily for 3 days, then once daily for another 11 days.
tumor imaging. All rats were prepared for CT imaging using a Siemens Inveon PET/CT Scanner at the 
Monash Biomedical Imaging (MBI) Facility, Clayton, Victoria, Australia on day 11 post-tumor injection. Prior 
to imaging, the rats were pre-warmed under a heat lamp before anaesthesia induction using 5% isoflurane. The 
rats were maintained at 2.5–3% isoflurane for CT imaging, and warmed with a heat mat. Vital signs monitored 
and maintained.
An iodine contrast agent, Iomeron-350 (Regional Health Care Group, Rosebery, NSW & Bracco Ltd), was 
used to visualize the tumor against the normal brain tissue. Before iodine injection, the tail was warmed to dilate 
veins in the tail. The tail was disinfected with water and 70% (v/v) ethanol before a 24 G ¾” Teflon catheter was 
inserted into the lateral tail vein. 1 mL of iodine was gradually injected (an initial 0.3 mL bolus over 10 s, and the 
remaining 0.7 mL over 4 minutes) using a pump for imaging during the 8 minute CT acquisition. Rats were posi-
tioned on small couch bed with ear bars to keep the skull level in the field. CT was acquired at 80 kVp energy and 
200 ms exposure in a 8.7 cm by 8.7 cm field-of-view. Final pixel size was 97 µm. Rats were given oxygen to recover 
from anaesthesia following imaging, and warmed in isolation, before returning to their home cage.
The tumor positions were determined with respect to the bony anatomy of the rat. The position of a tumor 
at day 11 in coronal, horizontal and sagittal views inside the head is shown in Fig. 2 for the rat containing the 
smallest tumor (surviving rat).
MRT. On day 12, 5 rats received MRT in hutch 2B on IMBL with each rat receiving 15 Gy in the valley at the 
target depth of 5.5 mm. 5 rats remain untreated for survival and behavioral comparison. Prior or after MRT, rats 
willingly ingested 1.5 mg/kg meloxicam as a preventative measure for inflammation following MRT.
After induction with 5% isoflurane, rats were maintained under general anaesthesia at 2.5–3% isoflurane while 
warmed with heat mats and heat lamp. Vital signs including respiratory rate and temperature were monitored as 
previous. Rats were mounted on the Kopf stereotaxic frame without the microinjection unit using a bite block and 
ear bars. The frame was secured on the treatment stage, securing the rat vertically, with the beam directed through 
the top of the skull (Fig. 3D). A heat lamp was used for warming during the treatment.
Individual tumors were aligned in the MRT field using an image guidance method developed for pre-clinical 
radiotherapy applications on IMBL36 and the CT image. The IMBL image guidance system (SyncMRT)36, was 
adapted to allow isocentric tumor positioning in the MRT array. 2 planar X-rays of each rat were taken prior 
to MRT, using an X-ray tube and detected on a Hamamatsu flat panel detector. The total imaging dose of the 
micro-CT scan and the planar X-ray to the skin was 8.91 ± 0.24 cGy (as determined using a MOSkinTM detector37).
The X-ray images were then co-registered with the CT image of bony landmarks obtained using the Inveon 
PET/CT. Landmarks for co-registration between the CT image and the X-ray image were verified within 
±0.1 mm, between the anterior and posterior orbits of the eyes, across the bregma line and the length of the skull. 
Once the X-ray image was aligned with the CT image, the tumor position was targeted by the alignment system. 
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The stage holding the Kopf stereotaxic frame was rotated and translated in 4 degrees of freedom accordingly for 
each rat to ensure tumor coverage in the 8 × 8 mm2 field. This unidirectional field is equivalent to the planning 
treatment volume (PTV), and fully contains the gross tumor volume (GTV). Figure 3 summarizes the alignment 
procedure.
Once the image alignment was performed, the rat was treated with MRT. Immediately prior to treatment, 2 
pieces of Gafchromic® film were placed anterior and posterior to the tumor position, to verify the MRT irradia-
tion delivery location. The single fraction, unidirectional, MRT delivery was performed using 3 T, 81 keV mean 
energy X-ray microbeams according to Table 1. Tumor dose coverage was achieved by moving the target (and 
mask) vertically at a rate of 0.5 mm/s, translating the 0.5 mm high intrinsic MRT field in the cranial to caudal 
direction on each rat. With this speed, the prescribed dose of 15 Gy in the valley was delivered at the tumor depth, 
shown in Fig. 1.
As part of the ethically approved animal management plan during the investigation, diazepam was given 
(4 mg/kg) by intra-peritoneal injection following MRT and after recovery to prevent over-stimulation of rats in 
recovery.
Rats were monitored for the effects of tumor growth twice daily up to day 200, after which monitoring fre-
quency was changed to once daily. Weight changes, neurological signs, gait, mobility, porphyrin staining, surgical 
site inflammation, and signs of discomfort were scored. In accordance with humane endpoints defined in the 
ethics approval, animals were euthanized if scoring exceeded normal values in these categories, or scored cumu-
latively in neurological signs, gait, mobility surgical site inflammation and weight categories. Death was not used 
as an endpoint in any part of this project.
tissue processing. After euthanasia (following the scoring of clinical signs), the brain of each rat was 
removed by opening the top of the skull and placed immediately in 10% neutral buffered formalin for immersion 
fixation. Fixed brains were sliced transversely, processed routinely through graded alcohols and xylene, embed-
ded in paraffin, and 4 µm sections stained with haematoxylin and eosin. Histology images were acquired using 4x 
magnification on a Nikon® Eclipse TS100 microscope with a Teledyne Lumenera® Infinity2 (5 MP USB digital 
color) microscope camera.
Retrospective treatment planning with MRT. For the first time, treatment planning has been imple-
mented to describe the long-term survival outcomes following MRT irradiation of 9LGS. Combining all infor-
mation from the simulation, dosimetry, imaging, and in vitro studies, the first patient-specific MRT treatment 
planning was performed for brain cancer.
CT images of each rat were processed through MATLAB®38 to distinguish tumor margins and determine 
the volume of each tumor as it varies with depth. The 8 × 8 mm2 microbeam field entirely covered the tumor in 
each rat, such that any variation dose coverage occurred only with depth from the surface of the skin. In this way, 
tumor dose was evaluated for each rat using the predicted Monte Carlo dose, and verified with dose calculations 
as 12.5 mm depth in Solid Water® only. For this study, cortical bone and realistic rat geometry was not included. 
Combining this information with the CT derived tumor volume distribution, dose-volume histograms (DVHs) 
of each tumor were obtained. The whole brain volume (excluding the gross tumor volume) was also considered 
as an organ at risk (OAR).
Results
cell response to broad synchrotron radiation. First, the effect of synchrotron radiation on 9LGS cells 
in vitro was compared to conventional orthovoltage X-rays. The major difference between the conventional kilo-
voltage and synchrotron therapies is the rate at which dose is delivered, as mean energies are comparable (see 
Table 1). Figure 4 compares the SBB treatments, detailed in Table 1, with the conventional 150 kVp orthovoltage 
X-rays.
For the same dose range, the impact of increasing the dose rate was synonymous with an increase in 9LGS 
cell death. The dose rates at the level of the cells using synchrotron 2 T and 3 T wiggler strengths are 40 Gy/s 
and 205 Gy/s, respectively, compared to the 0.76 Gy/min used with conventional X-rays. Only at a dose rate of 
205 Gy/s are significant cell lethality differences noted between the conventional treatment. Cellular dose rate 
dependence is also seen with FLASH radiotherapy39, in favor of normal tissue protection and with equivalent 
tumor responses. However, our result indicates a greater dose rate influence on the 9LGS cell line, that could 
produce not only better normal tissue sparing, but radiosensitization of the tumor.
Table 2 summarizes the radiobiological parameters. The most significant change to the radiobiological param-
eters is the change in the linear component, α. Ranging from 0.124 to 0.740 Gy−1, the greatest factor in the change 
to α is the dose rate of the radiation treatment. The RER10 is largest for the high dose rate 3 T treatments due to the 
dose rate response of the cells and the increase in β also.
cell response to synchrotron microbeam radiation therapy. Figure 5 compares the cell survival of 
9LGS using CBB, SBB, or MRT using a 2 T wiggler field. MRT produces more cell death than CBB or SBB when 
evaluating the cell survival against the valley dose. This is due to the increased lethality produced by the peak 
dose. The change in shape of the cell survival trend does not appear to be linear quadratic when including low 
doses. The gradient of the survival curve changes and is a function of the individual peak and valley population 
survivals. At high doses, the cell survival curve tends to follow the trend of the low dose rate SBB or CBB survival 
of 9LGS, offset by the population of cells that are abolished in the peak.
Overall MRT causes greater reduction in cell survival compared to SBB for the 2 T low dose rate result (Fig. 5). 
Ideally, for the treatment of 9LGS, a higher dose rate in the valley is required to replicate the important drop in cell 
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survival seen with the 3 T SBB in Fig. 4. Based on these results, the pre-clinical study was optimized in the next 
section using a 3 T wiggler field, as shown in Table 1.
Pre-clinical 9LGS Treatment. MRT was performed according to Table 1, with 15 Gy in the valley at the 
center of the tumor centered in the beam. MRT caused short-term and temporary symptomatic radiation-induced 
edema in 3 rats, which presented as seizing. Some seizing symptoms were present up 4.5 days after MRT, with the 
majority of symptoms noticed 2 hours – 1 day after MRT. Meloxicam and diazepam were used for the remaining 
rats to reduce the risk of seizure activity.
The survival of all rats treated with MRT compared to the non-irradiated group is shown in Fig. 6. MRT 
treated rats showed significantly longer survival than non-irradiated rats. The mean survival time (MST) and 
median survival time (MeST) with non-irradiated rats was found to be 20 and 21 days, respectively. In com-
parison the MST and MeST for rats treated with 3 T Cu/Al, using 15 Gy in the valley, was 135 and 44 days, 
respectively. The increase in lifespan (ILS) due to the MST and MeST is therefore 570% and 110%, respectively. 
These results represent the first long-term animal survival study at the Australian Synchrotron. No long-term 
adverse effects were observed following MRT, and there was no noticeable decline in cognition, vision, mobil-
ity, or behavior in treated rats. These observations were made longitudinally twice daily by the same observers. 
Informal observations were made of rat behavior and ability to learn and remember skills for food rewards (see 
Supplementary Video). We observed no significant changes to personality or social behavior and were able to 
remember commands and develop new skills for food before and after MRT. Rat behavior was seen to change 
only when brain cancer reoccurred.
Histological analysis of the brain was performed to observe the effect of microbeams on the brain and tumor 
tissue with respect to time. Figure 7 shows the 9LGS tumor and surrounding normal tissue over time, as stained 
with H&E.
The histological appearance of the 9LGS tumor in untreated rats was consistent with that in published descrip-
tions20,39. Tumors were not encapsulated with locally invasive margins (Fig. 7E–G) and were composed of ple-
omorphic, occasionally multinucleate spindle cells with a moderate number of mitotic figures. 1 day after MRT 
(day 13), H&E staining showed dark tumor cells in reoccurring tracks, corresponding to microbeam peak spacing 
of 400 μm (Fig. 7F). With time and persistent tumor growth, (Fig. 7G), microbeam tracks were no longer present 
due to repopulation of tumor cells. On closer inspection, cells resembling lymphocytes were detected 1–4 weeks 
after MRT infiltrating the tumor (Fig. 7G) with some focal edema. In the case of complete recovery and tumor 
ablation (Fig. 7H), some scar tissue was observed in the region with a large supporting vasculature structure.
In the normal brain, no microbeam tracks were distinguishable using H&E staining 1 day after MRT on day 
13 (Fig. 7F), however there was evidence of perivascular vacuolation, indicative of edema. By day 32 (Fig. 7B), 
microbeam tracks became visible in the normal brain. Between microbeam tracks, normal tissue was indistin-
guishable from normal untreated brain, highlighting the tissue sparing effect of MRT. Over time (Fig. 7C,D), 
microbeam tracks become fainter and distorted in normal tissue. At day 60, one rat had small mineralizations 
(orange in color in Fig. 7C) present throughout the tissue. In the cured rat (day 528), fewer microbeam tracks 
were seen in the brain. Figure 7D shows some of the more distinguishable microbeam tracks found. Very little 
mineralization was present and some vacuoles or necrosis were seen where microbeam tracks existed.
Despite deficits in cells along microbeam tracks, no pathologic features were observed in between the 
microbeams, and the animals did not experience a decline in cognition or signs of abnormal behavior throughout 
their lives. Cancerous tissue clearance was seen to be aided by heightened immune activity 1–4 weeks after MRT 
in the form of accumulating lymphocytes within the tumor, which plays a key role in cancer elimination, and 
has been reported elsewhere6. Some features such as collapsed vasculature (Fig. 7C) was noted, and also seen by 
Barbone et al. We did observe some calcification in tissue after 1 year, however, Barbone et al. observed signif-
icantly more 1.5 months after MRT, perhaps due the larger 9LGS size at the time of treatment (treated day 15).
Retrospective MRT treatment planning. To understand the factors contributing to successful MRT 
outcomes, a homogenous treatment planning approach was adopted using the CT data of each rat to determine 
the tumor volume distribution with respect to depth. This is a first approximation of patient-specific treatment 
planning for MRT using CT imaging, in vitro results, and Monte Carlo dose coverage. The results are shown in 
Fig. 8 for rats surviving 32, 44, 60, and 528 days after tumor implantation.
Figure 6. Fischer rat survival post 9LGS implantation for non-irradiated and MRT treated rats with 3 T MRT 
(see Table 1).
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Using the volume distribution in Fig. 8A, a dose volume histogram (DVH) was generated for each rat. The 
dose coverage of individual tumor volumes were computed using the experimentally validated Monte Carlo peak 
and valley doses. Furthermore, the dose with depth to the brain OAR, was assessed. Figure 8B shows the results 
for each of the rats in Fig. 8A, including the dose coverage to the brain OAR. Using the tumor DVH, there is a 
correlation between the tumor-dose coverage and survival in Fig. 8. The best coverage of the tumor volume with 
15 Gy resulted in the complete survival case.
Table 3 reviews the tumor coverage shown in the Fig. 8 and evaluates the equivalent uniform dose (EUD). 
EUD was derived in each case according to Eq. 1, using the simple EUD (Gy) calculation method outlined by 
Niemierko40.
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Over each partial tumor volume or voxel, vi, up to a total number of voxels, N, the corresponding dose, Di, is 
related to a reference dose, Dref, chosen from the in vitro MRT data at 8 Gy with corresponding survival (SF8Gy). 
This reference dose was chosen, rather than the previously used 2 Gy reference40, to avoid using the in vitro data 
that includes viable cells in the microbeam peak (as described in section Cell response to synchrotron microbeam 
radiation therapy). 8 Gy is also the minimum valley dose tumor voxels may receive.
While tumor volume was related to the treatment success, the overall survival was related to dose coverage. 
The tumor coverage varied between each rat due to the differences in tumor volumes with depth. As a result, the 
proportion of each tumor that received 15 Gy varied. This was seen to have consequences for survival when exam-
ining the remaining physical volume of 9LGS tumor that received less than 15 Gy. The likelihood for tumor recur-
rence increased proportionally with the tumor volume not covered by the 15 Gy isodose curve. Other parameters 
including the dose to 90% of the tumor showed that 14.7 Gy produced the most successful survival outcomes. In 
reviewing the DVH data, the most important factors in survival appear to be the tumor volume receiving 15 Gy 
rather than the total tumor volume or the dose to 90% of the tumor volume.
For the OAR, 21% of the whole brain received 8 Gy, with 12% of the whole brain receiving less than 15 Gy. 
2.8% of the brain received the peak dose of 800–1000 Gy.
Discussion
In this study, we developed a new framework for reporting and designing future MRT procedures for brain can-
cers, which, due to inherent radioresistance, require more rigorous and novel treatment strategies. The in vitro 
irradiation of 9LGS predetermined the tumor response before treating in vivo, similar to personalized medicine 
studies41,42. Typically, predicting radio-curability involves analysis of biopsies43, or potential biomarkers42,44–46. 
The response of 9LGS towards specific treatments such as MRT or broad beam in our study offered a means 
of clarifying certain trends in tumor sensitivity to radiation directly before in vivo treatment. Conventional 
Figure 7. Rat brain histology using H & E staining. The 9LGs tumor was located in the caudate putamen/
striatum. The normal tissue was compared in the striatum and cortex. Normal tissue in untreated rat, day 20 
(A), and MRT treated rats at day 32 (B), day 60 (C), and day 528 (D) after tumor implantation. Untreated tumor 
at day 20 (E), is compared to MRT treated tumors at days 13 (F), and 44 (G). Complete tumor ablation, leaving 
only scar tissue, day 528 (H). Microbeam tracks indicated with arrows, tumor supporting vasculature (*), tissue 
vacuolation (+) 1 day after MRT.
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kilovoltage radiotherapy of 9LGS (shown previously47), identified the significant radioresistance of cells at clinical 
dose rates (in order of <1 Gy/min). Synchrotron radiation was superior to conventional X-rays in the treatment 
of 9LGS if delivered at a dose rate of 205 Gy/s. This expands on previous findings48, showing that the 9LGS can be 
radiosensitized using synchrotron high dose rate fields, similar to FLASH therapies39.
MRT irradiations of 50 µm microbeams spaced at 400 µm peak-to-peak. Previous studies suggest that MRT 
survival can be correlated to broad beam conditions using the valley dose9, and this approach was adopted for 
this study. However, the cell survival curves showed two distinct trends of dose-effect relationships, depending 
on the MRT valley dose. MRT irradiation with a valley dose greater than 3 Gy exhibits a similar trend to SBB; only 
cells in the valley region are viable, with cells in the peak receiving lethal radiation doses. For valley doses lower 
than 3 Gy, however, cells within microbeam peaks are viable, further decreasing the overall cell survival compared 
to SBB for doses <3 Gy. Thus, this dose range is where MRT could be most beneficial compared to broad beam, 
either as a stand-alone treatment or in combination with other normal tissue sparing strategies. These could 
Figure 8. 9LGS tumor volume distribution with respect to physical depth from the surface of the skin (A) was 
measured from microCT images (top-left) and used to develop MRT dose volume histograms (B) for the gross 
tumor volumes (GTV) of rats surviving 32 days, 44 days, 60 days, and 528 days compared to the whole brain 
(OAR). CT datasets were thresholded for the tumor using MATLAB 2018. Limits in accuracy are produced 
due to the finite pixel size of 97 µm by 97 µm. Monte Carlo evaluated MRT dose with depth was verified 
dosimetrically at 12.5 mm as described in the Methods.
Rat 
Survival 
(days)
Tumor 
Volume 
(mm3)
Tumor Volume 
Receiving 15 Gy (%)
Tumor Volume Receiving 
less than 15 Gy (mm3)
Dose to 90% 
Volume (Gy)
EUD
(Gy)
32 8.42 53.58 3.91 14.4 15.3
44 1.38 26.02 1.02 13.2 14.6
60 1.72 44.57 0.95 14.7 15.3
528 0.59 72.22 0.16 14.7 15.4
Table 3. Summary of rat survival after tumor implantation and other contributing factors including tumor 
volume, the tumor volume receiving 15 Gy, dose to 90% of the tumor volume and the EUD evaluated using cell 
survival parameters.
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include clinical dose fractionation schemes or experimental dose enhancement techniques (such as nanoparticle 
radiosensitization).
The broad beam dose rate of 205 Gy/s could not be achieved in the valley, due to the beam collimation for 
MRT. However, this must be considered in the future, to benefit from both FLASH and the radiosurgical proper-
ties of MRT. A possible method of implementing this may be through cross-fired or interlaced MRT49, but this is 
at the expense of greater normal tissue exposure. Without dose rate dependence, MRT increased 9LGS cell death 
compared to lower dose rate broad beam irradiations, SBB (40 Gy/s) and CBB (0.76 Gy/min), due to the radio-
surgery of the microbeam peaks.
The in vivo MRT results followed the expectations of the in vitro experiments and were a product of rigorous 
dosimetry and tumor alignment with the MRT field.
With a MST of 135 days and MeST of 44 days, we have superior survival to the cross-fired treatment of Le 
Duc et al.10 and Regnard et al.17,50, and some of the unidirectional treatments of Dilmanian et al.16. However, it 
is difficult to directly compare between studies due to differing dose rates, beam geometry, tumor volume51 and 
unknown dose coverage of the tumor. The result from Regnard et al.17 predicts a 12.6 Gy valley dose at tumor 
depth and has a similar MeST of 40 days to our study, but with less overall survival.
By guaranteeing treatment accuracy and considering patient health, the survival outcomes reflect the expecta-
tions of tumor dose coverage of 15 Gy for 9LGS cells and long-term quality of life. The normal tissue sparing and 
radiosurgery of MRT was verified using histology results (Fig. 7). The microbeams caused an early response in 
the tumor 24 hrs after MRT, leading to immune-mediated clearance of 9LGS debris 2–4 weeks later. The normal 
tissue instead recovered over time, to show little difference between untreated and treated brain tissue. Only faint 
microbeam tracks remain in the brain 72 weeks after MRT. Moreover, MRT made no significant impact on rodent 
weight gain and growth, or had any noticeable behavioral effects. The 9LGS tumor was cured in 1 rat (which has 
been rehomed after no cancer was detected 1 year later).
There were, however, differences in the survival that could be a result of disparities in tumor size and location. 
The previous approach of using a dose of 15 Gy at 5.5 mm depth has been adopted in other studies6,10,16, but is not 
synonymous with treatment success. By considering true dose coverage, using CT imaging and dosimetrically 
verified Monte Carlo MRT doses, the first individualized treatment planning in MRT for 9LGS was retrospec-
tively performed to understand links between rodent survival and tumor dose-volume coverage. While tumor 
size was a factor, tumor ablation was ensured if 72% of the tumor volume received 15 Gy, with an EUD of 15.4 Gy. 
Future studies must include treatment planning before MRT, to assess adequate tumor coverage, and further min-
imize normal brain (OAR) doses. To remedy the variations in dose with depth, a bolus may be used to increase 
the depth for shallow tumors. By performing treatment planning and adjustments to tumor depth for each rat 
prior to treatment, MRT outcomes can be largely improved.
Whilst the survival outcomes were promising in this study, short-term complications occurred, such as tem-
porary symptomatic radiation-induced cerebral edema after MRT. Other treatments have not reported these 
short-term symptoms, including MRT performed at the European Synchrotron Research Facility (ESRF) using 
18 Gy in the valley. What is shown in previous studies such as Fardone et al.24, is that MRT does not have long 
term effects on the sensorimotor cortex. The temporary symptoms seen in our investigation therefore may be due 
to the larger field size or lower dose rate used on the IMBL compared to in vivo studies at the ESRF, which may, as 
a result, produce different normal tissue tolerances. It was further postulated that the use of isoflurane anaesthe-
sia, rather than ketamine-based anaesthesia used in other MRT studies10,15, causes more inflammation. Isoflurane 
provides better recovery but produces higher heart rates and blood pressure compared to ketamine52. Isoflurane 
may also increase the blood oxygen supply to the tumor, hence, the improvement in radiation treatment in vivo53. 
The initial inflammation may be reduced if the symptoms can be managed correctly, as no lasting effects in this 
study were seen with the use of Diazepam and Meloxicam. Anti-inflammatory strategies will be investigated fur-
ther in future MRT studies at IMBL, to determine management techniques.
conclusion
This study provides the first long term MRT animal survival study at the Australian Synchrotron. It identifies the 
key mechanisms involved in understanding the treatment outcomes of MRT as a brain cancer treatment modality. 
Thanks to ‘personalized’ in vitro cell modelling, pre-clinical MRT was optimized. Using state-of-the-art advanced 
dosimetry, Monte Carlo, and image guidance, precise in vitro and in vivo MRT was performed.
Histology results supported the survival data and indicated the stages in tumor control, or repopulation, after 
MRT, including normal tissue recovery. For the first time, recommendations for analgesia and sedation were 
reported, to allow for better recovery and symptom management. Individualized treatment planning for brain 
cancer MRT was implemented to find tumor coverage and other factors contributing to optimum MRT outcomes.
In this study, 8-week-old 9 LGS rats were treated with MRT. Without long-term side effects, this adolescent 
rat model has promising outcomes for treatment for children with brain cancer, which is often associated with 
high risks to quality of life. This study highlights the key advantages and strategies for improved brain cancer 
MRT using a small animal model. Normal tissue sparing, radiosurgical tumor control, and exceptional long-term 
quality of life were achieved. These developments are the first steps towards personalized clinical strategies using 
MRT. The extension of this work to larger animals is required, but may ultimately improve the outcome for young 
patients with brain cancer.
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